A web-based intervention to promote physical activity in adolescents and young adults with cystic fibrosis: protocol for a randomized controlled trial.
Application
Exercise
Goal setting
Online
Physical fitness
Telerehabilitation
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
19 Dec 2019
19 Dec 2019
Historique:
received:
28
07
2019
accepted:
20
09
2019
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
2
6
2020
Statut:
epublish
Résumé
Regular participation in physical activity by people with cystic fibrosis (CF) promotes positive clinical and health outcomes including reduced rate of decline in lung function, fewer hospitalizations and greater wellbeing. However adherence to exercise and activity programs is low, in part due to the substantial daily therapy burden for young people with CF. Strict infection control requirements limit the role of group exercise programs that are commonly used in other clinical groups. Investigation of methods to promote physical activity in this group has been limited. The Active Online Physical Activity in Cystic fibrosis Trial (ActionPACT) is an assessor-blinded, multi-centre, randomized controlled trial designed to compare the efficacy of a novel web-based program (ActivOnline) compared to usual care in promoting physical activity participation in adolescents and young adults with CF. Adolescents and young adults with CF will be recruited on discharge from hospital for a respiratory exacerbation. Participants randomized to the intervention group will have access to a web-based physical activity platform for the 12-week intervention period. ActivOnline allows users to track their physical activity, set goals, and self-monitor progress. All participants in both groups will be provided with standardised information regarding general physical activity recommendations for adolescents and young adults. Outcomes will be assessed by a blinded assessor at baseline, after completion of the intervention, and at 3-months followup. Healthcare utilization will be assessed at 12 months from intervention completion. The primary outcome is change in moderate-to-vigorous physical activity participation measured objectively by accelerometry. Secondary outcomes include aerobic fitness, health-related quality of life, anxiety and depression and sleep quality. This trial will establish whether a web-based application can improve physical activity participation more effectively than usual care in the period following hospitalization for a respiratory exacerbation. The web-based application under investigation can be made readily and widely available to all individuals with CF, to support physical activity and exercise participation at a time and location of the user's choosing, regardless of microbiological status. Clinical trial registered on July 13, 2017 with the Australian and New Zealand Clinical Trials Register at (ACTRN12617001009303).
Sections du résumé
BACKGROUND
BACKGROUND
Regular participation in physical activity by people with cystic fibrosis (CF) promotes positive clinical and health outcomes including reduced rate of decline in lung function, fewer hospitalizations and greater wellbeing. However adherence to exercise and activity programs is low, in part due to the substantial daily therapy burden for young people with CF. Strict infection control requirements limit the role of group exercise programs that are commonly used in other clinical groups. Investigation of methods to promote physical activity in this group has been limited. The Active Online Physical Activity in Cystic fibrosis Trial (ActionPACT) is an assessor-blinded, multi-centre, randomized controlled trial designed to compare the efficacy of a novel web-based program (ActivOnline) compared to usual care in promoting physical activity participation in adolescents and young adults with CF.
METHODS
METHODS
Adolescents and young adults with CF will be recruited on discharge from hospital for a respiratory exacerbation. Participants randomized to the intervention group will have access to a web-based physical activity platform for the 12-week intervention period. ActivOnline allows users to track their physical activity, set goals, and self-monitor progress. All participants in both groups will be provided with standardised information regarding general physical activity recommendations for adolescents and young adults. Outcomes will be assessed by a blinded assessor at baseline, after completion of the intervention, and at 3-months followup. Healthcare utilization will be assessed at 12 months from intervention completion. The primary outcome is change in moderate-to-vigorous physical activity participation measured objectively by accelerometry. Secondary outcomes include aerobic fitness, health-related quality of life, anxiety and depression and sleep quality.
DISCUSSION
CONCLUSIONS
This trial will establish whether a web-based application can improve physical activity participation more effectively than usual care in the period following hospitalization for a respiratory exacerbation. The web-based application under investigation can be made readily and widely available to all individuals with CF, to support physical activity and exercise participation at a time and location of the user's choosing, regardless of microbiological status.
TRIAL REGISTRATION
BACKGROUND
Clinical trial registered on July 13, 2017 with the Australian and New Zealand Clinical Trials Register at (ACTRN12617001009303).
Identifiants
pubmed: 31856791
doi: 10.1186/s12890-019-0942-3
pii: 10.1186/s12890-019-0942-3
pmc: PMC6921562
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Références
J Am Coll Health. 2004 Jan-Feb;52(4):181-8
pubmed: 15018429
Int J Behav Nutr Phys Act. 2011 Sep 19;8:97
pubmed: 21923955
Chest. 2006 Mar;129(3):536-44
pubmed: 16537849
Chest. 2004 Jan;125(1 Suppl):1S-39S
pubmed: 14734689
J Cyst Fibros. 2007 May;6(3):163-70
pubmed: 16904388
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Respirology. 2016 Apr;21(3):511-8
pubmed: 26715596
Med Sci Sports Exerc. 2008 Jan;40(1):181-8
pubmed: 18091006
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Pediatr Pulmonol. 2002 Mar;33(3):194-200
pubmed: 11836799
Cochrane Database Syst Rev. 2017 Nov 01;11:CD002768
pubmed: 29090734
Med Sci Sports Exerc. 2005 Nov;37(11 Suppl):S531-43
pubmed: 16294116
Pediatr Pulmonol. 2008 Apr;43(4):345-53
pubmed: 18306334
Respir Care. 2015 Mar;60(3):422-9
pubmed: 25425703
Am J Respir Crit Care Med. 2019 Apr 15;199(8):987-995
pubmed: 30321487
Data Brief. 2016 Nov 09;9:926-930
pubmed: 27896298
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Arch Dis Child. 2012 Nov;97(11):960-6
pubmed: 22984185
Cochrane Database Syst Rev. 2013 Dec 13;(12):CD009448
pubmed: 24338214
J Pediatr. 2000 Mar;136(3):304-10
pubmed: 10700685
BMC Pulm Med. 2018 May 15;18(1):71
pubmed: 29764393
J Cyst Fibros. 2015 Nov;14(6):e25-32
pubmed: 26219990
J Cyst Fibros. 2014 May;13 Suppl 1:S23-42
pubmed: 24856775
Psychiatry Res. 2013 Dec 30;210(3):812-8
pubmed: 24182688
J Sports Sci. 2008 Dec;26(14):1557-65
pubmed: 18949660
Eur Respir J. 2010 Mar;35(3):578-83
pubmed: 19643946
Chest. 2011 Apr;139(4):870-877
pubmed: 20829339
Pediatr Pulmonol. 2009 Oct;44(10):989-96
pubmed: 19768806
Chest. 2004 Apr;125(4):1299-305
pubmed: 15078738
Respirology. 2016 May;21(4):656-67
pubmed: 27086904
Lancet. 1993 Apr 24;341(8852):1065-9
pubmed: 7682274
Thorax. 2014 Dec;69(12):1090-7
pubmed: 25246663
J Telemed Telecare. 2012 Mar;18(2):72-8
pubmed: 22198961
Thorax. 1999 May;54(5):437-9
pubmed: 10212110
Chest. 2005 Oct;128(4):2347-54
pubmed: 16236893
Chest. 2000 Jun;117(6):1666-71
pubmed: 10858400